The historical rank and industry rank for Biotechnology Assets's Net Margin % or its related term are showing as below:
XMAD:BST'
s Net Margin % Range Over the Past 10 Years
Min: -473.33 Med: -92.13 Max: 43.71
Current: -62.02
XMAD:BST's Net Margin % is ranked better than 53.17% of 946
companies
in the Biotechnology industry
Industry Median: -88.815
vs XMAD:BST: -62.02
Biotechnology Assets (XMAD:BST) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Biotechnology Assets Net Margin % Related Terms
Biotechnology Assets Net Margin % Historical Data
* Premium members only.
The historical data trend for Biotechnology Assets's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XMAD:BST vs VRTX, REGN, ALNY: Net Margin % Comparison
For the Biotechnology subindustry, Biotechnology Assets's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biotechnology Assets Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Biotechnology Assets's Net Margin % distribution charts can be found below:
* The bar in red indicates where Biotechnology Assets's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biotechnology Assets (XMAD:BST) has a Net Margin % of -51.28% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Biotechnology Assets and its competitors. According to the industry distribution chart, Biotechnology Assets ranks #443 out of 946 companies in the Biotechnology industry, placing it in the top 46.8%.
Is Biotechnology Assets' Net Margin % too high?
Biotechnology Assets' current Net Margin % is -51.28%. Based on the distribution chart, Biotechnology Assets ranks #443 out of 946 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Biotechnology Assets has a GF Score™ of 19/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Biotechnology Assets' Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Biotechnology Assets ranks #443 out of 946 companies for Net Margin %. This puts Biotechnology Assets in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Biotechnology Assets and its competitors. Biotechnology Assets's current Net Margin % is -51.28%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biotechnology Assets stock overvalued right now?
Based on GuruFocus' analysis, Biotechnology Assets (XMAD:BST) is currently considered Modestly Undervalued. The stock's GF Value™ is €0.30, compared to a current price of €0.23 — trading 24.7% below its estimated fair value. The current Net Margin % is -51.28%. Biotechnology Assets' overall GF Score™ is 19/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Biotechnology Assets (XMAD:BST), the current Net Margin % is -51.28% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biotechnology Assets (XMAD:BST) Overvalued in 2026?
Based on GuruFocus' analysis, Biotechnology Assets stock appears to be undervalued.
The current stock price of €0.23 is trading 24.7% below its estimated GF Value™ of €0.30.
GuruFocus considers Biotechnology Assets to be Modestly Undervalued.
Key valuation signals for XMAD:BST:
Net Margin %: -51.28%
GF Value™: €0.30 vs. price of €0.23 (24.7% below fair value)
No single metric tells the full story. See the XMAD:BST stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biotechnology Assets SA is a clinical-stage biopharmaceutical company developing and producing biological products for the pharmaceutical and veterinarian sectors. It specializes in the prevention and treatment of niche diseases, such as orphan disease, antigens for new-generation vaccines, feed additives, and probiotics. Adl Bionatur offers a portfolio of non-therapeutic and therapeutic products to tier 1 and tier 2 animal health companies. The company's pipeline products include BNT006, BNT007, BNT010, and others.
19GF Score
Get the complete analysis for XMAD:BST
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAD:BST has been successfully added to your 
